Market News

UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.

As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook.  

The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.

The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden...

The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. 

With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. 

Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. 

ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. 

Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. 

In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...

On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya...

Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. 

Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.  

In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. 

In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...

The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. 

In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.

The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...

The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). 

Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...

Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.

A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. 

Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. 

What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? 

Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. 

In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe. 

A carefully curated list of the most notable drug approvals of the past year, covering neurology, oncology, and COVID-19, as well as a look at the most promising drugs up for review in 2023. 

Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. 

Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. 

Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution

Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why. 

The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility.

Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access.

The health body recommended use of treatments by Regeneron and Ridgeback Bio

Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market

Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation

The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally 

In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ...

Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine

Companies that are further down the road to market are more attractive to investors than those in early development 

VLA15 is the only Lyme disease vaccine candidate currently in clinical development 

The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat 

Smaller companies targeting rare and extremely specific treatment areas are leading the charge in this emerging market.  

The $3.3 billion deal will strengthen GSK’s vaccine pipeline. 

The site will produce customisable bioprocess container systems. 

Samsung Biologics has full ownership over Samsung Bioepis after purchasing Biogen’s stake

The investment will expand operations over two years at facilities in Taiwan and Canada

Asahi plans to use the CDMO to propel its bioprocess business

Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am...

Drugmakers have agreed to speed up the market launch of new drugs in underserved EU member states as an alternative to stricter regulation. 

The expansion includes the addition of automated and high-speed production lines. 

Construction of Plant 4 – dubbed Super Plant – will be complete in 2023 

TraceLink’s Product Availability Intelligence will enable stakeholders to predict drug shortages months in advance  

Germany forms more than half of the EU’s medical cannabis market  

Sanofi will reduce its stake in EUROAPI to 30% after listing 

Symbiosis, Freeline Therapeutics and Cell and Gene Therapy Catapult joined forces to decrease drug manufacturing timelines

The German healthcare group says the acquisitions will accelerate strategic growth in biopharmaceuticals and MedTech 

International pharma companies may do well to consider setting up shop in the Netherlands, according to data compiled by Mercator by Citco

The expansion will provide additional cold storage and visual inspection capacity, as well as cleanrooms for device assembly and secondary packaging

The expansion will take two years and add 180 new jobs. 

Many clinical trials have been put on hold or cancelled due to the war in Ukraine 

Market set to grow as companies face fewer operational restrictions and COVID-19 drug development continues at pace

Bristol Myers Squibb to leverage Volastra’s CINtech platform to discover and develop oncology drug candidates.  

A redeveloped R&D facility will enhance Seqens' capabilities in developing and producing APIs and active delivery systems development

The CDMO will produce drug substance for clinical supply at its HPAPI manufacturing site in Nansha, China

KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide. 

The CDMO has expanded its ultra-low temperature commercial packaging, labelling and distribution solutions facility in Ireland

The largest sums of capital were awarded to US biotech companies, followed by companies based in Mainland China and the UK

The development and cGMP manufacturing laboratories will provide additional early-phase HPAPI manufacturing capabilities

The Taiwan-based nebuliser specialist has signed an MoU with Formosa Laboratories, and Formosa Pharmaceuticals to form a biopharma one-stop-shop

Public funding of more than €7 million will help the project to find a solution to prohibitive production costs of developing stem cell-based therapies

By joining forces, the two companies will be able to bring Dispersome to the market faster for novel drug development

The two transactions enable Recipharm to expand its ATMP offering into virotherapies and boost its US biologics services

MediCane Health's EU-GMP certification helps to bridge the pharma-cannabis gap

A diverse range of sectors and industries come together in partnership to address infection management, advocating a whole system approach

The investment covers two expansions to accommodate several pipeline products moving to commercial scale

The $1.5 billion investment will fund a parenteral manufacturing facility in North Carolina and a biopharmaceutical manufacturing site in Ireland

Initial Public Offerings totalled £1,304 million, an increase of 434% from 2020, but more needs to be done to connect the UK's life sciences and finance sectors

Xpress Pharmaceutics will facilitate adaptive clinical trials and reduce the time taken to complete FIH studies

The collaboration includes a multimillion-dollar investment to expand glass technology that will advance packaging and delivery systems

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain. Includes the latest news surrounding the therapeutic developments, updates to vaccines and boosters, and the global pharmaceutical regulations that need t...

The agreement will enable millions of patients in more than 100 low- and middle-income countries to gain access to molnupiravir

Last year the company reduced its electricity requirements by 40%

The CDMO will provide expertise and capacity to advance BravoBio's vaccine pipeline

The move is expected to bring added value to customers by coupling biology services with existing chemistry capabilities

This second facility gives the company a significant power multiplier for export capacity and geographical reach

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates

CDMO currently manufacturing LAAB combination treatment  and will start on cancer immunotherapy product from next year

Merck will design the manufacturing process to help accelerate self-sufficient vaccine development and manufacturing in West Africa

The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets

The dedicated pharma trade lane will unite key compliant and sector-certified supply chain stakeholders and help Abu Dhabi to strengthen its capabilities as a life sciences hub

The new facility will focus on the research of excipients for oral dosage forms, drug delivery systems, nutraceutical APIs and innovative pharma ingredients

CPHI has launched its forward-looking pharma trend report for 2022 and it is now available to read on CPHI Online.

A 30,000-sq. ft cGMP facility and a separate R&D site will work alongside each other to provide end-to end product development solutions for Singapore and low- and middle-income countries

The facility will be the first to use Evolve’s innovative PlasmaCap EBA technology to produce plasma-derived therapeutics

The combined company intends to lead in the space of oral formulations, solving customers' complex formulation challenges

It could take pharmaceutical companies months to tweak their COVID-19 vaccines to provide sufficient protection against the Omicron variant of the coronavirus if it poses a risk of serious illness.

The new route uses a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug

The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies

The expansion is expected to make the company the largest CDMO in oligonucleotide production in 2025

The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing

The transaction expands ANI’s R&D pipeline and adds nine new customers to its growing CDMO business

The facility's total 60,000-L capacity supports growing demand for manufacture of late-phase and commercial projects

China is the pharma industry’s biggest gainer in the 2021 CPHI Annual Rankings, with digital matchmaking driving new waves of partnerships

The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects

SK's financial backing enables CBM to address significant capacity constraints in the cell and gene therapy manufacturing space

The proposed state-of-the-art facility could potentially produce up to 100 million vaccine doses each year for Australians

WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide

The $20.1 million investment will enable the company to manufacture pharma products for the Adcock Ingram Group and for other clients

The transaction will support Cannabics' planned IND fillings and Phase I/II (a) clinical trials

The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast

The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPHI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market

Expected increase in approvals for gene therapies, gene-modified cell therapies and recombinant vector vaccines will also increase pressure on manufacturers to build new capacity

The CDMO says the suite will help to "bring back manufacturing to the US"

The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies

The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts

The CDMO's services will help to advance clinical testing of Clearmind's drug candidate for treating alcohol use disorder

Clients to receive accelerated quality testing and reduced turnaround times